Swarm Oncology
Despite the promise of immunotherapy, metastatic solid tumours remain untreatable. Current approaches face significant limitations, including toxicity, inefficacy in solid tumours, and reliance on pre-existing immune responses. There is an urgent need for a broadly applicable therapy that generates a powerful, sustained cellular immune attack on advanced solid cancers.
Our mission is to apply Swarm’s proprietary technology to T cell therapy modalities. We develop autologous therapies to improve the clinical outcome across solid tumour indications for cancer patients.
